96 related articles for article (PubMed ID: 38464520)
1. Opportunities and challenges for anti-CD47 antibodies in hematological malignancies.
Xu Y; Jiang P; Xu Z; Ye H
Front Immunol; 2024; 15():1348852. PubMed ID: 38464520
[TBL] [Abstract][Full Text] [Related]
2. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
[TBL] [Abstract][Full Text] [Related]
3. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint.
Wu ZH; Li N; Mei XF; Chen J; Wang XZ; Guo TT; Chen G; Nie L; Chen Y; Jiang MZ; Wang JT; Wang HB
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256517
[TBL] [Abstract][Full Text] [Related]
5. Targeting HDAC6 improves anti-CD47 immunotherapy.
Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
[TBL] [Abstract][Full Text] [Related]
6. Targeting macrophages in hematological malignancies: recent advances and future directions.
Li W; Wang F; Guo R; Bian Z; Song Y
J Hematol Oncol; 2022 Aug; 15(1):110. PubMed ID: 35978372
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Tang L; Huang Z; Mei H; Hu Y
Signal Transduct Target Ther; 2023 Aug; 8(1):306. PubMed ID: 37591844
[TBL] [Abstract][Full Text] [Related]
8. Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system.
Ye L; Lv W; He W; Li S; Min Z; Gong L; Zhang Q; Teng C; Sun S; Lv L; Guo Y; Xin H
J Control Release; 2023 Jul; 359():224-233. PubMed ID: 37290721
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
[TBL] [Abstract][Full Text] [Related]
10. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Sallman DA; Al Malki MM; Asch AS; Wang ES; Jurcic JG; Bradley TJ; Flinn IW; Pollyea DA; Kambhampati S; Tanaka TN; Zeidner JF; Garcia-Manero G; Jeyakumar D; Komrokji R; Lancet J; Kantarjian HM; Gu L; Zhang Y; Tan A; Chao M; O'Hear C; Ramsingh G; Lal I; Vyas P; Daver NG
J Clin Oncol; 2023 May; 41(15):2815-2826. PubMed ID: 36888930
[TBL] [Abstract][Full Text] [Related]
11. The landscape overview of CD47-based immunotherapy for hematological malignancies.
Yang H; Xun Y; You H
Biomark Res; 2023 Feb; 11(1):15. PubMed ID: 36726125
[TBL] [Abstract][Full Text] [Related]
12. The clinical impact of the molecular landscape of acute myeloid leukemia.
Kayser S; Levis MJ
Haematologica; 2023 Feb; 108(2):308-320. PubMed ID: 36722402
[TBL] [Abstract][Full Text] [Related]
13. CD47: Beyond an immune checkpoint in cancer treatment.
Bian HT; Shen YW; Zhou YD; Nagle DG; Guan YY; Zhang WD; Luan X
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188771. PubMed ID: 35931392
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
